Written By: Biomeme Staff
We are thrilled to announce Biomeme, Inc. has been awarded a Redevelopment Assistance Capital Program (RACP) grant of $3 million from the Commonwealth of Pennsylvania. This RACP Grant will enable our expansion into a new 40,000 square foot space to increase our operations and manufacturing capacity. This project entails the build-out to support manufacturing and development to produce over 10 million tests annually.
The Redevelopment Assistance Capital Program (RACP) is a Commonwealth grant program administered by the Office of the Budget for the acquisition and construction of regional economic, cultural, civic, recreational, and historical improvement projects.
Our new facility will expand manufacturing of our mobile RT-PCR devices, production of our FDA emergency use authorized test assays in 3 formats (Go-Strips™, Go-Plates™, and Bulk Vials), and the production of our sample preparation products, which extract and purify the DNA/RNA from a sample.
We’ve grown exponentially since the beginning of the COVID-19 pandemic and throughout the last year. Since March 2020, our team has quadrupled, allowing Biomeme to increase local manufacturing capacity to address the continued need for fast and reliable COVID-19 Real-Time RT-PCR tests worldwide. Continued expansion of our research & development, manufacturing and operations will allow us to offer increased access to fast and accurate testing at a pivotal time while vaccines roll out and we continue to see COVID cases on the rise. We look forward to staying in Center City Philadelphia and plan to complete our new headquarters later this year.
Thank you to all of our staff and local partners for making this possible!
Get the latest tips from Biomeme shipped right to your inbox
As a company, we measure our progress in the diagnostics we develop and deliver and the impact we have on global health. But awards are nice, too. So we were humbled and honored to receive the PACT...